Ativo Capital Management LLC Sells 4,393 Shares of Icon Plc (ICLR)

Ativo Capital Management LLC decreased its stake in shares of Icon Plc (NASDAQ:ICLR) by 15.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,264 shares of the medical research company’s stock after selling 4,393 shares during the quarter. Ativo Capital Management LLC’s holdings in Icon Plc were worth $2,275,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ICLR. Canada Pension Plan Investment Board increased its holdings in Icon Plc by 155.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 13,140 shares of the medical research company’s stock worth $1,048,000 after purchasing an additional 8,000 shares during the period. US Bancorp DE increased its holdings in Icon Plc by 15.0% during the 1st quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after purchasing an additional 251 shares during the period. Bank of New York Mellon Corp increased its holdings in Icon Plc by 4.0% during the 1st quarter. Bank of New York Mellon Corp now owns 310,788 shares of the medical research company’s stock worth $24,777,000 after purchasing an additional 11,892 shares during the period. World Asset Management Inc increased its holdings in Icon Plc by 1.8% during the 1st quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock worth $275,000 after purchasing an additional 60 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in Icon Plc by 2.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 239,769 shares of the medical research company’s stock worth $19,114,000 after purchasing an additional 4,951 shares during the period. Institutional investors own 90.61% of the company’s stock.

Several equities research analysts have weighed in on ICLR shares. Jefferies Group LLC upgraded Icon Plc from a “hold” rating to a “buy” rating and upped their price target for the stock from $86.00 to $117.00 in a report on Thursday, June 29th. Goldman Sachs Group, Inc. (The) upgraded Icon Plc from a “buy” rating to a “conviction-buy” rating and set a $117.00 price target on the stock in a report on Friday, July 7th. Credit Suisse Group restated an “outperform” rating and set a $102.00 price target (up previously from $91.00) on shares of Icon Plc in a report on Tuesday, June 6th. Zacks Investment Research upgraded Icon Plc from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Tuesday, June 27th. Finally, BidaskClub upgraded Icon Plc from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $113.00.

Icon Plc (ICLR) traded down 0.14% on Tuesday, hitting $113.23. The stock had a trading volume of 239,425 shares. Icon Plc has a 12-month low of $73.76 and a 12-month high of $117.53. The firm has a market cap of $6.12 billion, a PE ratio of 22.97 and a beta of 0.61. The company’s 50 day moving average is $108.49 and its 200 day moving average is $93.78.

Icon Plc (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The business had revenue of $431.00 million for the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The company’s revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Icon Plc will post $5.32 EPS for the current fiscal year.

WARNING: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/19/ativo-capital-management-llc-sells-4393-shares-of-icon-plc-iclr.html.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply